Published Date: 13 May 2024
DFS after three years was 87% after six years as opposed to 55% after three, but the toxicity was higher.
Read Full NewsBritish lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...
In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.
Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.
Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.
In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.
For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.
1.
Taking Charge of Your Cancer Journey.
2.
Accuracy of Skin Cancer Diagnosis Varies by Physician, Exam Method
3.
FDA Approves Next-Gen Agent for Mantle Cell Lymphoma
4.
Mixed Results With Cyclophosphamide in Mismatched Unrelated Stem Cell Transplants
5.
Cancer screening rates down among American adults
1.
Cerebrospinal Fluid Metabolite Biomarkers in Central Nervous System Tumor Monitoring: A New Frontier
2.
Role of Type I Interferons and KDM1B in Driving Cancer Stemness and Therapeutic Evasion
3.
Precision Medicine and Genomics: Revolutionizing Healthcare Through Personalized Treatment
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Metabolic Heterogeneity and Tumor Persistence: Mechanisms, Clinical Implications, and Emerging Strategies
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
4.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation